Good morning :)
$
₹
Revolution Medicines Inc

Revolution Medicines Inc

RVMD

NASDAQ
Asset Logo

Revolution Medicines Inc

RVMD

NASDAQ
$183.082.08% (-3.90)
$
₹
$183.082.08% (-3.90)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Large Cap

With a market cap of $40.1B the stock is ranked 387

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

16.11
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-8.87
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 25 analysts reports

Buy
24 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+38.43%

Earnings Growth

-62.11%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.68
80.68
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.28
27.28
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.90
29.90
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
662.28%
662.28%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 38.43% growth, versus a trailing 3-year CAGR of 116.78%.

2026
Current$186.99Baseline
Analyst Target - 1 year
Target$258.84+38.43%

All values in $

202220232024202520262027$87.26$153.08$218.90Target+38.43%
2026
Current$186.99Baseline
Analyst Target - 1 year
Target$258.84+38.43%

All values in $

Revenue Forecast

Revenue Forecast

2025
Current$0Baseline
Forecast for Dec 2026
High$354.66
Average$200.81
Low$45.05

All values in $ Million

20212022202320242025202629.3935.3811.5800LowAverageHigh
2025
Current$0Baseline
Forecast for Dec 2026
High$354.66
Average$200.81
Low$45.05

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-5.91Baseline
Forecast for Dec 2026
High$-8.21-38.92%
Average$-9.58-62.11%
Low$-12.17-105.92%

All values in $

202120222023202420252026-2.56-3.1-3.77-3.57-5.91Low-105.92%Average-62.11%High-38.92%
2025
Current$-5.91Baseline
Forecast for Dec 2026
High$-8.21-38.92%
Average$-9.58-62.11%
Low$-12.17-105.92%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-305.2
-364.8
-453.8
-644.3
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue000261.59000000
Net Income-116-133.23-156.28-194.56-213.41-247.78-305.20-364.89-453.81-644.37
Net Profit Margin----74.37%------
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Revolution Medicines Inc -16.11-
AbbVie Inc80.6850.450.53
Amgen Inc27.2817.562.28
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare RVMD with any stock or ETF
Compare RVMD with any stock or ETF
Comparing from
RVMD
ABBV
AMGN
Loading...

Frequently asked questions

  1. Revolution Medicines Inc (RVMD) share price today is $183.08 as of October 27, 2026 at 12:18 AM IST. The stock touched a day high of $187.92 and a day low of $181.30.

  2. Revolution Medicines Inc stock trades on NASDAQ under the ticker symbol RVMD.

  3. Revolution Medicines Inc's market capitalization is $40.07B as of October 27, 2026 at 12:18 AM IST.

  4. Revolution Medicines Inc's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Revolution Medicines Inc's price-to-book (P/B) ratio is 16.11 as of October 26, 2026.

  6. Yes, You can buy Revolution Medicines Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Revolution Medicines Inc shares in three steps: 1. Search Revolution Medicines Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Revolution Medicines Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Revolution Medicines Inc (RVMD) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0546 shares at the current price of $183.08.

Loading...